BioprintingMedical AMProfessional Additive Manufacturing

International Stem Cell Corporation Presents New Liver Tissue Bioprinter

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

International Stem Cell Corporation, a California-based clinical stage biotechnology company, has developed a 3D bioprinter which utilizes proprietary liver progenitor cells (LPC), which differentiate into cholangiocytes, hepatocytes and stellate cells. For this type of liver tissue bioprinter, once 3D liver-like structures are produced from the LPC, they are expected to provide a treatment for various liver diseases once transplanted into the damaged liver. The LPC can be derived from any kind of pluripotent stem cells, including human embryonic, induced pluripotent, or parthenogenetic stem cells, via ISCO’s proprietary highly efficient and scalable differentiation method.

“I’m excited to announce that we have developed a new efficient technology to produce 3D liver tissue, which may be able to replace damaged tissue to restore liver functions. Additionally, the developed liver tissue  potentially can be used not only in liver treatment, but also in drug discovery as a model for drug screening, which opens up a potential multi-billion market for ISCO” commented Russell Kern, PhD., Executive Vice President and Chief Scientific Officer of ISCO. “We have already developed a master cell bank of the liver progenitor cells and, we are proceeding to test safety and efficacy of the cells in various models of liver diseases like liver cirrhosis and fibrosis” he continued.

The Liver (Gall Bladder Removed)

According to the American Liver Foundation, approximately 17,000 patients are on the U.S. liver transplant waiting list with only 6,000 liver transplants performed each year. Currently, there are no alternatives available for patients in need of a liver transplant other than to join the waiting list. Cirrhosis is the end stage in patients who have chronic progressive liver disease. While liver transplantation is a viable treatment option for these candidates, increasing waiting times for organ transplantation has led to the deaths of nearly 17% of those who were on the waiting list.

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of human pluripotent stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

Research
Consumer Products AM 2024

1,346 polymer and metal AM companies and 143 end-users. Consumer products AM generated $2.6 billion in 2023. Segment expected to grow to $28 billion by 2033 at 26.8% CAGR. This new market study fro...

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.